Weekly shot may shield joints in hemophilia a patients
NCT ID NCT06752850
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 25 times
Summary
This study tests whether a once-weekly medicine called efanesoctocog alfa can improve joint health in 37 people with moderate or severe hemophilia A. Researchers will use ultrasound and MRI to check for joint swelling and damage over 12 months. The goal is to see if the treatment reduces joint bleeds and slows or reverses joint problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sobi Investigational Site
Milan, Italy
-
Sobi Investigational Site
Naples, Italy
-
Sobi Investigational Site
Rozzano, Italy
-
Sobi Investigational Site
Oslo, Norway
-
Sobi Investigational Site
Barcelona, Spain
-
Sobi Investigational Site
Madrid, Spain
-
Sobi Investigational Site
Seville, Spain
-
Sobi Investigational Site
Valencia, Spain
-
Sobi Investigational Site
Gothenburg, Sweden
-
Sobi Investigational Site
Malmö, Sweden
Conditions
Explore the condition pages connected to this study.